Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: Journal of Medical Internet Research

Date Submitted: Jan 22, 2021
Date Accepted: Nov 10, 2021

The final, peer-reviewed published version of this preprint can be found here:

A Remote Monitoring System to Optimize the Home Management of Oral Anticancer Therapies (ONCO-TreC): Prospective Training–Validation Trial

Passardi A, Foca F, Caffo O, Tondini C, Zambelli A, Vespignani R, Bartolini G, Sullo F, Andreis D, Dianti M, Eccher C, Piras EM, Forti S

A Remote Monitoring System to Optimize the Home Management of Oral Anticancer Therapies (ONCO-TreC): Prospective Training–Validation Trial

J Med Internet Res 2022;24(1):e27349

DOI: 10.2196/27349

PMID: 35080505

PMCID: 8829690

Clinical validation of a remote monitoring system (ONCO-TreC) to optimize the home management of oral anticancer therapies

  • Alessandro Passardi; 
  • Flavia Foca; 
  • Orazio Caffo; 
  • Carlo Tondini; 
  • Alberto Zambelli; 
  • Roberto Vespignani; 
  • Giulia Bartolini; 
  • Francesco Sullo; 
  • Daniele Andreis; 
  • Marco Dianti; 
  • Claudio Eccher; 
  • Enrico Maria Piras; 
  • Stefano Forti

ABSTRACT

Background:

ONCO-TreC, a platform designed to support the home management of anticancer oral treatments and to provide a secure online patient-healthcare professional communication modality, was tested in 3 cancer centers in Italy.

Objective:

The overall aims of the trial were to customize the platform, assess the system’s ability to facilitate the shared management of oral anticancer therapies by patients and health professionals, and evaluate system usability and acceptability by patients, caregivers and healthcare professionals.

Methods:

Patients ≥18 years old who were candidates for anticancer oral treatment as monotherapy, with an ECOC PS 0-1 and a sufficient level of familiarity with mobile devices, were eligible. Forty patients were enrolled, and adherence was >86%.

Results:

The ability of the system to measure adherence to treatment was high, with a concordance of 97.3% (95 CI: 86.1%-99.9%) between investigator and system pill count. Only 60.0% of grade (G)3, 54.1% of G2 and 19.4% of G1 adverse events reported by physicians in Case Report Forms were also reported in the mobile application (APP) directly by patients. 94.2% of patients had at least one APP launch each week, and the median number of daily accesses per patient was 2. Twenty-seven (77.1%) and 26 patients (74.2%) used the application for messages and vital sign entering, respectively, at least once during the study period.

Conclusions:

ONCO-TreC was an important tool for measuring and monitoring adherence to oral anticancer drugs. System usability and acceptability were very high, whereas its reliability in registering toxicity could be improved. Clinical Trial: ClinicalTrials.gov NCT02921724; https://www.clinicaltrials.gov/ct2/show/NCT02921724


 Citation

Please cite as:

Passardi A, Foca F, Caffo O, Tondini C, Zambelli A, Vespignani R, Bartolini G, Sullo F, Andreis D, Dianti M, Eccher C, Piras EM, Forti S

A Remote Monitoring System to Optimize the Home Management of Oral Anticancer Therapies (ONCO-TreC): Prospective Training–Validation Trial

J Med Internet Res 2022;24(1):e27349

DOI: 10.2196/27349

PMID: 35080505

PMCID: 8829690

Per the author's request the PDF is not available.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.